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Abstract PPARQ is a member of the peroxisome proliferator
activated receptors (PPAR) subfamily of nuclear receptors. So
far two PPARQ isoforms, PPARQ1 and PPARQ2, were known in
mammals. We describe the structure of a novel human PPARQ
subtype, PPARQ3. The PPARQ3 mRNA is transcribed from a
novel promoter localized 5P of exon A2. PPARQ3 mRNA
expression was restricted to adipose tissue and large intestine.
Similar to human PPARQ1 and -2, PPARQ3 is activated by
thiazolidinediones and prostaglandin J derivatives and binds with
high affinity to a PPRE.
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1. Introduction
The peroxisome proliferator activated receptors or PPARs
are a subfamily of the nuclear hormone receptor gene super-
family. So far three distinct PPARs, K, N, and Q, each encoded
by a separate gene and with a speci¢c tissue distribution have
been described. Two important ¢ndings recently underscored
the importance of the PPARQ transcription factor. First,
PPARQ has been identi¢ed as one of the key factors control-
ling adipocyte di¡erentiation and function [1,2], hinting to a
potential role for it in metabolic disorders linked to abnormal
adipose tissue physiology, such as obesity and non-insulin
dependent diabetes mellitus (NIDDM); second, the recent
identi¢cation of prostaglandin J2 derivatives and thiazolidine-
diones as, respectively, natural and synthetic PPARQ ligand
[3^7]. Thiazolidinediones are a new group of anti-diabetic
drugs which improve insulin resistance (reviewed in [8,9]).
These observations have generated a major interest in the
role of this PPAR subtype in normal and abnormal adipocyte
function in man.
We recently determined the gene structure of the human
PPARQ gene and started studying its regulation and expres-
sion. When analyzing the expression of human PPARQ, a
novel subtype, PPARQ3, was identi¢ed. The expression of
this PPARQ3 mRNA was directed by an independent pro-
moter and was con¢ned to adipose tissue and colon epithe-
lium. The PPARQ3 mRNA gave rise to a protein indistin-
guishable from PPARQ1. PPARQ3 expression was, like
PPARQ2, restricted to colon and adipose tissue in man. The
identi¢cation of a third independent promoter suggests a com-
plex regulation of the PPARQ gene expression and allows a
more accurate regulation of this transcription factor.
2. Materials and methods
2.1. Materials and oligonucleotides
The oligonucleotides used for various experiments in this manu-
script are listed in Table 1. BRL 49 653 was a kind gift of Dr. A.
Nazdan of Ligand Pharmaceuticals. All chemicals, except if stated
otherwise, were purchased from Sigma (St. Louis, MO, USA).
2.2. RNA isolation, primer extension, and RNase protection assays
Total cellular RNA was prepared as described previously [10]. For
primer extension, the oligonucleotide LF-60 was 32P-labelled with T4-
polynucleotide kinase (Amersham, Courtaboeuf, France) to a speci¢c
activity of 107 dpm/50 ng and puri¢ed by gel electrophoresis. Primer
extension analysis was performed using 50 Wg of total RNA and
105 dpm of radiolabelled oligonucleotide according to a standard
protocol utilizing a mixture of 1.25 U AMV reverse transcriptase
(Life Technologies, Paisley, UK) and 100 U MMLV reverse transcrip-
tase (Life Technologies, Paisley, UK). A sequencing reaction was used
as molecular mass standard to map the 5P end of the extension prod-
ucts.
The absolute mRNA concentration of the di¡erentially spliced
PPARQ variants was measured by RNase protection assay exactly
as described [11]. The full length PPARQ2 coding region plus 33 bp
of the 5P-UTR was ampli¢ed from human adipose tissue RNA by RT-
PCR with the primer pair LF-3/LF-36 and was inserted in inverted
orientation (3P to 5P in front of the T7 promoter) into the EcoRI site
of the expression vector pSG5 (Stratagene, La Jolla, CA, USA). The
resulting plasmid pSG5-hPPARQ2-inv was digested with EcoRV and
religated, yielding the vector pSG5-hPPARQ2-RPA, which was used as
a template for the synthesis of the anti-sense RNA probe, to measure
the amounts of PPARQ2 relative to PPARQ1 and 3 mRNA. For the
speci¢c analysis of the PPARQ3 mRNA relative to PPARQ1, another
probe template was constructed by RT-PCR from human adipose
tissue RNA with the primer pair LF-44 (which binds to the sense
strand in exon A1) and LF-21 (which binds to the antisense strand
in exon 2). The ampli¢ed fragment, which contains part of exon A1,
the full length exon A2, exon 1, and part of exon 2, was inserted into
the EcoRV site of pBluescript SK to generate the plasmid pBSQ3-
RPA. For the analysis of mouse PPARQ RNA, mPPARQ cDNA was
ampli¢ed, using the same strategy and oligonucleotides described
above to create the vector pSG5-mPPARQ2-inv. This plasmid was
digested by EcoRI and religated resulting in the plasmid pSG5-
mPPARQ-RPA. The in vitro synthesized probe contains part of exons
4 and 5 of the mPPARQ gene.
2.3. Tissue biopsies and cell culture
Omental adipose tissue, small and large intestine, kidney, muscle,
and liver biopsies were obtained from non-obese adult subjects under-
going elective surgery or endoscopy. All subjects had fasted overnight
before surgery (between 8.00 p.m. and 10.00 a.m.) and received intra-
venous saline infusion. They had given informed consent, and the
project was approved by the ethics committee of the University of
Lille. All tissue was immediately frozen in liquid nitrogen until RNA
preparation. Standard cell culture conditions were used to maintain
3T3-L1 (ATCC), CV-1 (a kind gift from Dr. R. Evans), THP-1
(ATCC), HeLa (ATCC), CaCo2 (ATCC) and HepG2 cells (ATCC).
In certain experiments supercon£uent di¡erentiated CaCo2 cells were
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used. BRL 49 653 (in DMSO) was added to the medium at the con-
centrations and times indicated. Control cells received vehicle only.
2.4. Isolation of the human PPARQ3 cDNA
In order to isolate the full length PPARQ3 cDNA, RT-PCR was
performed using the primer pair LF-65 (binding at the beginning of
exon A2 of the human PPARQ gene) and LF-36 (binding at the stop
codon) and human adipose tissue RNA as template. The resulting
ampli¢ed fragment was cloned blunt into the EcoRV site of pBlue-
script SK (Stratagene, La Jolla, CA, USA) and sequenced on an
ABI 377 automatic sequencer (Applied Biosystems, Foster City,
CA, USA). The fragment containing the full length PPARQ3 cDNA
was then cloned into vector pcDNA3 (Invitrogen, Leek, The Nether-
lands) resulting in the expression vector pcDNA3-hPPARQ3 which
was used in both transfection and gel-shift experiments.
2.5. Analysis of promoter activity and transactivation assays
The PAC clone P-8856 [12], containing the full length PPARQ gene,
was sequenced with the oligonucleotides LF-60 and LF-63 pointing
upstream of exon A2. A 800-bp fragment of the PAC clone 8856 was
isolated by PCR using the amplimers LF-60 (binding to the antisense
strand in exon A2) and LF-68 (binding sense at position 3800 of the
PPARQ3 promoter). This PCR fragment was sequenced, inserted into
the EcoRV site of pBluescript SK (Stratagene, La Jolla, CA, USA),
and after SpeI and KpnI restriction subcloned into pGL3 (Promega,
Madison, WI, USA), creating the reporter vector pGL3Q3p800. Trans-
fections, luciferase and L-galactosidase assays were generally per-
formed as described previously [13].
2.6. Electrophoretic mobility shift assays (EMSA) and oligonucleotide
sequences
hPPARQ3 and mRXRK [14] proteins were synthesized in vitro in
rabbit reticulocyte lysate (Promega, Madison, WI, USA). Molecular
weights and quality of the in vitro translated proteins were veri¢ed by
SDS-PAGE. hPPARQ (2 Wl) and/or mRXRK (2 Wl) were incubated for
15 min on ice in a total volume of 20 Wl with 1 ng of T4-PNK end-
labelled AII-J-PPRE double-stranded oligonucleotide probe, 2.5 Wg
poly(dI:dC) and 1 Wg herring sperm DNA in binding bu¡er (10 mM
Tris-HCl (pH 7.9), 40 mM KCl, 10% glycerol, 0.05% Nonidet P-40
and 1 mM DTT). For competition experiments, increasing amounts
(from 10- to 200-fold molar excess) of cold oligonucleotide (AII-J-
PPRE [15]: 5P-GATCCTTCAACCTTTACCCTGGTAGA-3P) were
included just before adding labelled probe. DNA-protein complexes
were separated by electrophoresis on a 4% polyacrylamide gel in
0.25U TBE bu¡er at 4‡C [16].
3. Results
We have previously determined the sequence of the exon-
intron boundaries of the human PPARQ gene [12]. A more
detailed analysis of the 5P sequence boundaries of exon A2
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Fig. 1. RNase protection assay demonstrating the presence of a third PPARQ form (A) and schematic representation of the genomic structure
of the human PPARQ gene (B). A: RNase protection assay showing the presence of a band corresponding to an mRNA message containing
only exon A2 in both human omental white adipose tissue and in the human adenocarcinoma cell CaCo2. A scheme of the probe is indicated
at the right side of the autoradiograph. The bands corresponding to the undigested probe as well as the protected fragments corresponding to
PPARQ1 and PPARQ3 are indicated. B: A scheme of the genomic structure of the 5P end of the human PPARQ gene. Exons 1^6 are shared by
all three subtypes. PPARQ1 contains in addition the untranslated exons A1 and A2, PPARQ2 contains exon B, which is translated, and PPARQ3
contains only the untranslated exon A2.
Table 1
Oligonucleotides used in this study listed from 5P to 3P
LF60 cgttaaaggctgactctcgtttga
LF65 cgttaaaggctgactctcgtttga
LF36 gtcaccgaattctagtacaagtccttgtagatctcc
LF3 gtgaattacagcaaacccctattc
LF44 gtcggcctcgaggacaccggagag
LF63 gtcacatgaatgacgatacctc
LF68 tcatgtaggtaagactgtgtagaa
LF102 ctagcgtcattcatgtgacataaa
AII-J gatccttcaacctttaccctggtaga
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indicated the presence of some potential regulatory elements
such as a TATA and CCAAT box motif. These data sug-
gested the presence of a third promoter in the PPARQ gene,
which could lead to the production of an alternative PPARQ
mRNA species containing only exon A2 in its 5P-UTR. In
order to assess this possibility, an RNase protection assay
was performed using a radiolabelled probe containing both
the A1 and A2 untranslated exons plus a sequence common
for all PPARQ mRNAs, i.e. exon 1. In the presence of a PPARQ
mRNA species containing exclusively exon A2, this probe
would yield a protected fragment which is 42 bp shorter
than the fragment present in PPARQ1, which contains both
exons A1 and A2. These 42 bp correspond to the part con-
stituted by sequences from exon A1 present in the probe (Fig.
1A). Consistent with this idea, RNase protection assays of
RNA from adipose tissue and colonic CaCo2 cells, two tissues
which are known to express high levels of PPARQ, showed an
additional RNA species, di¡erent from PPARQ1 and -2. The
size of this new mRNA species corresponds to an RNA which
contains only exon A2 (Fig. 1A). Based on this information,
the structure of the 5P end of the human PPARQ gene corre-
sponds to the scheme represented in Fig. 1B.
We next performed primer extension experiments on human
adipose tissue RNA to identify the 5P end of this novel PPARQ
cDNA. One major primer extension product of 37 bp was
observed with the primer LF-60 (Fig. 2A). The length of the
extended product indicates that this new mRNA begins at the
initiation of exon A2. These data unequivocally demonstrate
the presence of an additional PPARQ transcription initiation
site giving rise to a new PPARQ mRNA which we designated
as PPARQ3. The PPARQ3 mRNA will, however, be translated
into a protein which is indistinguishable from PPARQ1 since
there is no translation initiation site in exon A2 (Fig. 2B). The
region 5P to the transcription initiation site of the PPARQ3
mRNA, which corresponds to the proximal PPARQ3 pro-
moter, was sequenced (Fig. 2B). Several consensus sequence
elements were identi¢ed. A TATA-like element was found at
334 relative to the transcription initiation site. Sequence anal-
ysis furthermore identi¢ed a potential CAAT-like consensus
C/EBP binding site at 3118 as well as a potential E-box bind-
ing site for the transcription factor ADD-1/SREBP-1 at posi-
tion 3342 (Fig. 2B).
To evaluate the activity and tissue speci¢city of this pro-
moter we cloned an 800-bp fragment, located immediately
upstream of the transcription initiation site of PPARQ3 into
the luciferase reporter vector pGL3 basic. The resulting plas-
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Fig. 2. Determination of the transcription initiation site of PPARQ3, sequence of proximal 5P regulatory region, and analysis of PPARQ3 pro-
moter activity. A: Primer extension of human white adipose tissue RNA with the PPARQ speci¢c primer LF-60 was performed as described in
Section 2. The major extension product is indicated by an arrow. Size standards, on the left, consist of a sequencing reaction. B: Sequence cor-
responding to the 5P-UTR of the PPARQ3 mRNA. Sequence motifs are indicated in bold (CCAAT box, TATA box). The oligonucleotide
LF-60 used for primer extension is indicated by the arrow. C: Relative activity of the PPARQ 3 promoter. Normalized luciferase activity of the
pGL3-Q3p800 reporter construct, containing 800 bp of PPARQ3 promoter, were determined after transient transfections in 3T3-L1, HepG2, and
THP-1 cells as described in Section 2. Results represent the mean þ the standard deviation of three independent experiments. Asterisks indicate
statistically signi¢cant di¡erences by Student’s t-test.
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mid pGL3Q3p800 was transfected into the mouse 3T3-L1 and
human HepG2 and THP-1 cell lines (Fig. 2C). Transfection
e⁄ciency was monitored by evaluation of the activity of a L-
galactosidase control vector. Relative to the promoterless par-
ent vector, the PPARQ3 promoter stimulated the luciferase
expression more than two-fold in HepG2 cells and in undif-
ferentiated 3T3-L1 cells (Fig. 2C). The activity of the PPARQ3
promoter was in the same range as the activity observed for
the PPARQ1 and -2 promoter in these cells (data not shown
and [12]). Interestingly, in THP-1 cells, a myeloid cell line,
expression of the PPARQ3 promoter was more than six-fold
higher than that of an promoterless control construct (Fig.
2C).
In order to study the relative expression of the three PPARQ
subtypes in di¡erent tissues we employed RNase protection
assays. Due to the complexity of the PPARQ gene we could
not quantitate in the same assay the relative levels of expres-
sion of the three PPARQ mRNA forms. Therefore we per-
formed two di¡erent assays (see Section 2 for the description
of the probes). The ¢rst RNase protection assay was designed
to determine the amount of PPARQ2 mRNA relative to
PPARQ1 and PPARQ3 mRNAs (Fig. 3A), whereas with the
second RNase protection assay we determined the amount of
PPARQ3 mRNA relative to that of PPARQ1 (Fig. 3B). The
expression of PPARQ3 mRNA is restricted to adipose tissue
and di¡erentiated CaCo2 cells (Fig. 3B, lanes 1 and 5). With
the exception of human white adipose tissue, none of the
tissues or cell lines analyzed contained substantial amounts
of PPARQ2 mRNA (Fig. 3A). In contrast to the tissue re-
stricted expression of the PPARQ2 and -3 mRNAs, PPARQ1
mRNA is more widely expressed and is detected in adipose
tissue, human hepatocytes, and the cell lines HepG2, CaCo2,
and HeLa (Fig. 3A,B).
Although sequence analysis suggested that the PPARQ3
protein should be identical to the protein product arising
from the PPARQ1 mRNA, we veri¢ed experimentally whether
the protein made from PPARQ3 expression vector has similar
characteristics. To analyze whether PPARQ3 could bind to a
PPRE, classically composed of direct repeats spaced by one
intervening nucleotide (DR-1), electrophoretic mobility shift
analysis (EMSA) was performed using in vitro transcribed/
translated PPARQ3 protein. An oligonucleotide containing a
high-a⁄nity PPRE, previously identi¢ed in the apo A-II pro-
moter J site, was used in EMSA. This oligonucleotide was
capable of binding the hPPARQ3/mRXRK heterodimers in
EMSA (Fig. 4A, lanes 4^6). Homodimers of either hPPARQ3
or mRXRK, however, were incapable of binding to this oli-
gonucleotide (Fig. 4A, lanes 2 and 3). These data hence prove
that the protein transcribed from PPARQ3 mRNA is identical
to the protein produced from the PPARQ1 mRNA in its ca-
pacity to bind to a PPRE.
Finally, we veri¢ed whether the human PPARQ3 cDNA was
also capable of activating gene transcription through a PPRE.
Therefore 3T3-L1 preadipocytes were cotransfected with the
PPARQ3 expression vector pcDNA3-hPPARQ3 and a PPRE-
driven luciferase reporter gene. The luciferase reporter gene
was under the control of a multimerized ACO-PPRE site and
the TK promoter (Fig. 4B). hPPARQ3 in the absence of ligand
was incapable of activating this PPRE-based reporter. How-
ever, in the presence of ligand a 1.5-fold activation was ob-
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Fig. 3. Analysis of the expression of the di¡erent PPARQ isoforms in human cells and tissues. A: RNase protection assay comparing the ex-
pression of PPARQ2 relative to PPARQ1 and PPARQ3 mRNA in the indicated tissues and cell lines. The RNA from the CaCo2 cells was ob-
tained from di¡erentiated cells, whereas that of THP-1 cells was from undi¡erentiated cells. The structure of the mRNAs as well as the probe
used in the assay is indicated in the top of the panel. B: RNase protection assay comparing the expression of PPARQ3 relative to PPARQ1 and
mRNA in the indicated tissues and cell lines (same as in panel A). The structure of the mRNAs as well as the probe used in the assay is indi-
cated in the top of the panel.
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served. This stimulatory e¡ect was substantially enhanced
when hPPARQ3 was cotransfected together with mRXRK.
Upon the addition of the PPARQ ligand BRL-14653, lucifer-
ase expression was increased at least 2.5-fold when the cells
were cotransfected with both hPPARQ3 and mRXRK. Similar
results were obtained when prostaglandin J2 was used as a
PPARQ ligand (data not shown).
4. Discussion
We have previously described the genomic structure of the
human PPARQ gene and isolated the promoters of both
PPARQ1 and PPARQ2 isoforms. While performing RNase
protection assays, we have found an unexpected band whose
length did not correspond with either the PPARQ1 or the
PPARQ2 mRNA species, suggesting the existence of an alter-
native PPARQ mRNA subtype, containing only the untrans-
lated exon A2, which we called PPARQ3. Several arguments
support the hypothesis that the expression of PPARQ3 mRNA
was directed by an independent promoter. First, primer ex-
tension assay indicates that there is a transcription initiation
site for a novel PPARQ3 mRNA subtype, consistent with the
observations of the RNase protection assay. Second, sequence
analysis of the intronic sequence immediately upstream of this
exon reveals the presence of di¡erent regulatory elements
(TATA box, CCAAT box) which can direct gene expression,
suggesting that these sequences could function as a promoter.
Finally and most importantly, this region functions as a pro-
moter in transient transfection experiments. Indeed, a frag-
ment spanning 800 bp upstream of exon A2 was able to direct
the expression of a heterologous luciferase reporter gene in
transient transfection assays, demonstrating it functions as a
promoter.
In agreement with previous studies, we show that the ex-
pression of the PPARQ gene is not restricted to adipose tissue.
Whereas the PPARQ1 isoform has a relative ubiquitous ex-
pression, both PPARQ3 and PPARQ2 expression is relatively
con¢ned to certain tissues. In fact, in RNase protection assays
PPARQ2 seems to be mostly restricted to adipose tissue where-
as PPARQ3 is expressed in both adipose tissue and colon
epithelium. In addition, in a previous manuscript we reported
high level expression of PPARQ3 in human macrophages [17],
which is consistent with the high level of activity of the
PPARQ3 promoter in activated THP-1 cells. How the produc-
tion of the di¡erent PPARQ subtypes is actually controlled is
unclear at present but the presence of di¡erent promoters
suggests that these di¡erent PPARQ subtypes might be impor-
tant in tissue-speci¢c regulation of gene expression. The ob-
servation that the tissues which reportedly express the highest
amount of PPARQ, i.e. adipose tissue, macrophage, and colon,
are also the only tissues which contain, in addition to the
more ubiquitous PPARQ1 form, additional PPARQ types
such as PPARQ2 and PPARQ3, suggests that these last might
be responsible for more ¢nely tuned control of gene expres-
sion. In addition, little is known about the function of the two
di¡erent proteins transcribed from the PPARQ gene, i.e.
PPARQ1 (translated either from the PPARQ1 and PPARQ3
mRNAs) and PPARQ2 (translated from the PPARQ2
mRNA). Although detailed side by side comparison of trans-
activation by PPARQ1 and PPARQ 2 has not been performed,
con£icting evidence exists in the literature concerning di¡er-
ences in activity between PPARQ1 and -2. In fact, on the one
hand it was shown that the NH-2 terminal of PPARQ2 might
be a better ligand-independent activator relative to PPARQ1
[18] ; on the other hand in other studies it was shown that
both forms have a similar capacity to induce adipocyte di¡er-
entiation [1,2].
In summary, in man there are three di¡erent subtypes of
PPARQ mRNA transcribed from three di¡erent promoters.
All three subtypes contain a common region spanning exons
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Fig. 4. Electrophoretic mobility shift analysis and transactivation assays demonstrating binding and transactivation of hPPARQ3/mRXRK heter-
odimers to a PPRE or PPRE driven reporter gene, respectively. A: hPPARQ3/mRXRK heterodimers bind to the AII-Jwt PPRE. EMSA was
performed with end-labelled AII-Jwt PPRE oligonucleotide in the presence of in vitro transcribed/translated hPPARQ3 and mRXRK or unprog-
rammed reticulocyte lysate in the absence or presence of increasing concentrations of unlabelled wild-type AII-Jwt PPRE oligonucleotide as de-
scribed in Section 2. B: Undi¡erentiated 3T3-L1 cells were cotransfected with the Jwt3-TK-CAT plasmid in the presence of an empty pSG5
expression vector or expression vectors encoding hPPARQ3, mRXRK, and both hPPARQ3 and mRXRK together. Cells were treated with
BRL-49653 (1 WM), or vehicle (DMSO) and CAT activity was measured and expressed as described in Section 2.
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1^6. In addition to the common exons, PPARQ1 contains
exons A1 and A2, PPARQ2 exon B and PPARQ3 exon A2.
PPARQ1 and PPARQ3 code for the same protein since exons
A1 and A2 are untranslated, whereas PPARQ2 codes for a
di¡erent protein which contains an additional 30 amino acids
at its N-terminus encoded by exon B. Further studies are
required to de¢ne the exact function of PPARQ in human
physiology.
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